No se ha encontrado

Chris Lee

@Vestin

9Lun·

News: $IBRX (-3,44 %) US FDA approves bladder cancer therapy from ImmunityBio!

Very positive for the rest of the pipeline ... lets go!

9 Comentarios

PaulPaulsonle@PaulPaulsonle

9Lun

I opened a mini position, I'm very excited

•

Fuchs89@nit

9Lun

a milestone in cancer therapy. I have been invested since 2021 and will hold for a long time

•

Chris Lee@Vestin

9Lun

@nit I am also invested and very confident. Great company and only at the beginning.

•

TrendingRobin@TrendingRobin

9Lun

Also invested since 2021 and looking forward to the development

•

Hugo_Offiziell@_Hugo_

9Lun

You did everything right 👍🏻. Once again, I hesitated too long 🙄

••

PaulPaulsonle@PaulPaulsonle

8Lun

Do any of you know why they have already risen 9% in pre-market trading today?
Greetings

••

Fuchs89@nit

8Lun

@PaulPaulsonle
https://finance.yahoo.com/news/immunitybio-executive-chairman-dr-patrick-120000920.html

Patrick Soon-Shiong will present the implications and results of N-803 (ANKTIVA) at the annual meeting of the AUA (American Urological Association).

••

PaulPaulsonle@PaulPaulsonle

8Lun

Thank you very much👌👌👌👌
I'm currently considering whether I should increase my position by a lot before the stock market opens in America😅
Do you think that's a good idea?

••

Fuchs89@nit

8Lun

@PaulPaulsonle I can't tell you, as I don't have a crystal ball ^^ With a market cap of over 5 billion, a lot of future performance is of course already priced in. Personally, I think that risk/reward is very attractive in both the short and long term. However, you should not rely on other opinions, but do your own research and adjust your position according to your risk management.
(not investment advice)

••